Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBT Margin (2016 - 2025)

Agios Pharmaceuticals' EBT Margin history spans 13 years, with the latest figure at 546.18% for Q4 2025.

  • For Q4 2025, EBT Margin rose 43611.0% year-over-year to 546.18%; the TTM value through Dec 2025 reached 769.18%, down 272752.0%, while the annual FY2025 figure was 765.89%, 273304.0% down from the prior year.
  • EBT Margin reached 546.18% in Q4 2025 per AGIO's latest filing, up from 803.05% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 11167.28% in Q3 2024 to a low of 12073.44% in Q1 2022.
  • Average EBT Margin over 4 years is 1187.98%, with a median of 1184.15% recorded in 2023.
  • Peak YoY movement for EBT Margin: soared 1240156bps in 2024, then plummeted -1197033bps in 2025.
  • A 4-year view of EBT Margin shows it stood at 2150.44% in 2022, then surged by 37bps to 1350.7% in 2023, then increased by 27bps to 982.28% in 2024, then soared by 44bps to 546.18% in 2025.
  • Per Business Quant, the three most recent readings for AGIO's EBT Margin are 546.18% (Q4 2025), 803.05% (Q3 2025), and 903.6% (Q2 2025).